Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 14/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721847 | 0.92 | MAP4K4 (0.50) | MAP4K4TGFBR1LMNA | |
| SCHEMBL22172385 | 0.92 | MAP4K4 (0.50) | MAP4K4TGFBR1LMNA | |
| SCHEMBL22172393 | 0.90 | MAP4K4 (0.55) | MAP4K4TGFBR1CLK4ADK | |
| SCHEMBL22180298 | 0.88 | MAP4K4 (0.51) | MAP4K4TGFBR1LMNAUSP2TP53 | |
| SCHEMBL30738227 | 0.88 | MAP4K4 (0.51) | MAP4K4TGFBR1LMNAUSP2TP53 | |
| SCHEMBL23988237 | 0.86 | MAP4K4 (0.57) | MAP4K4TGFBR1LMNAUSP2CYP1A2 | |
| SCHEMBL28444221 | 0.85 | MAP4K4 (0.52) | MAP4K4TGFBR1LMNAUSP2TP53 | |
| SCHEMBL29831651 | 0.85 | MAP4K4 (0.52) | MAP4K4TGFBR1LMNAUSP2TP53 | |
| SCHEMBL22172355 | 0.84 | MAPK14 (0.40) | MAP4K4TGFBR1USP2 | |
| SCHEMBL30721862 | 0.84 | MAPK14 (0.40) | MAP4K4TGFBR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166109-B | Aminopyridine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN-KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3904348-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3904348-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-11-03 | — | — | EP | disclosed |
| CN-113166109-A | Aminopyridine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020135195-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020135195-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA1, ADORA2A, ADORA2B | MAP4K4 4027/4885TGFBR1 2728/4885LMNA 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.